279P Prognostic significance of pre-treatment NLR and PLR in BRCA1-associated epithelial ovarian cancer–a retrospective analysis

Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis

“…Increasing evidence has indicated that inflammatory response might be involved in the occurrence and growth of various tumors [ 26 – 31 ]. And inflammation-related neutrophils and lymphocytes are also crucial to tumor growth, invasion, and metastasis.…”

“…Instead, lymphocytes are faithful anticancer defenders, and high lymphocyte counts have been proved as a favourable factor in terms of survival in a good way in many human cancers [ 38 , 39 ]. The abovementioned mechanism might indicate that high NLR is an unfavourable factor in most cancers [ 28 – 31 ].…”

“…In our meta-analysis, the results showed that high NLR was significantly associated with worse PFS when compared with the low NLR. And study conducted by Badora-Rybicka et al also covered that pretreatment high NLR was a negative prognostic factor for ovarian cancer in terms of PFS [ 31 ]. However, Zhang et al reported that high NLR was a favourable prognostic factor for ovarian cancer in terms of PFS (≤3.4 versus >3.4, HR = 2.012, 95% CI = 1.476–2.741, and p < 0.001) [ 19 ].…”

Prognostic significance of platelet‐to‐lymphocyte ratio in patients with ovarian cancer: A meta‐analysis

“…[10][11][12][13] These tests are simple and inexpensive to perform, and they are readily available in daily oncologic practice. [14][15][16] However, some studies failed to find the correlation between PLR and prognosis of ovarian cancer. Moreover, Tian and Song contributed equally to this work.…”

“…a high pretreatment PLR, which also reflects the degree of systemic inflammation, has been found to be linked to prognosis in patients with ovarian cancer. [14][15][16] However, some studies failed to find the correlation between PLR and prognosis of ovarian cancer. [17][18][19] We therefore conducted a metaanalysis to assess the prognostic effect of pretreatment PLR in ovarian cancer.…”